Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02945527
Other study ID # 62352
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date December 4, 2015
Est. completion date December 2018

Study information

Verified date April 2019
Source Universidad Peruana Cayetano Heredia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis


Description:

This study will evaluate 24 patients with calcified NCC and edema in three treatment arms to compare the reduction in edema volume


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Calcified NCC - Perilesional edema on CT or MRI - Normal lab values Exclusion Criteria: - Viable neurocysticercosis - Status epilepticus - Symptomatic intracranial hypertension - Tuberculosis - More than 7 days after seizure - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acetazolamide
As described above
Dexamethasone
As described above

Locations

Country Name City State
Peru Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas Lima

Sponsors (1)

Lead Sponsor Collaborator
Universidad Peruana Cayetano Heredia

Country where clinical trial is conducted

Peru, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in Volume of Perilesional Edema Between Baseline and Day 4 MRI extension of edema Baseline to Day 4
Secondary Decrease in Volume of Perilesional Edema Between Baseline and Day 8 MRI extension of edema Baseline to Day 8
Secondary Decrease in Volume of Perilesional Edema Between Baseline and Day 30 MRI extension of edema Baseline to Day 30
See also
  Status Clinical Trial Phase
Completed NCT00527579 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB Phase 1
Completed NCT00526916 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28 Phase 1
Terminated NCT02233855 - People Presenting With Neurocysticercosis in North America
Recruiting NCT00001205 - Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Completed NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Phase 1
Terminated NCT02947581 - Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Phase 3
Completed NCT02243644 - Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Phase 3
Not yet recruiting NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis Phase 4
Completed NCT03874689 - Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
Completed NCT00441285 - Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) Phase 2/Phase 3
Not yet recruiting NCT04706819 - Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Completed NCT00283699 - A Pilot Study of Neurocysticercosis Treatment Phase 3
Completed NCT00290823 - Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients Phase 3
Completed NCT03834337 - Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Completed NCT03851419 - The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania